TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

BBOT · Nasdaq · United States

Share price · BBOT

$1.80-7.14 (-79.83%) 3M

close as of 2026-11-18 · 24h delayed · vol 577K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BBOT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+16.4%
  2. 9 Nov 2026+12.7%
  3. 2 Nov 2026-11.8%
  4. 11 Sep 2026-10.3%
  5. 10 Sep 2026-18.3%
  6. 9 Sep 2026-23.8%
  7. 8 Jul 2026+8.8%
  8. 26 Jun 2026-3.8%
  9. 9 Jun 2026-6.7%
  10. 14 May 2026+5.3%

Share of unusual movement by asset

For each asset, the share of BBOT's own-move activity since 7 Aug 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
BBO-10203
events and moves
1shown from 8 days
BBO-11818
events and moves
1shown from 8 days
BBO-8520
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—8%
Other company news (earnings, financing, releases naming no asset)—10%
Sessions with no dated event—82%

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 1
RAS:PI3Kα protein-protein interactionSmall molecule
Non-Small Cell Lung CancerBreast CancerColorectal Cancer
HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer
Phase 1
Pan-KRASSmall molecule
Non-Small Cell Lung Cancer
Phase 1
KRAS G12CSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (11)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$30M$77M+ $117M short-term inv.$34M-$28M operating cash flowreport ↗
View 10 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$49M$54M+ $172M short-term inv.$56M-$44M operating cash flowreport ↗
2026-Q1—$40M$53M+ $200M short-term inv.$42M-$36M operating cash flowreport ↗
2025-Q4—$38M$374M+ $52M short-term inv.$39M-$42M operating cash flowreport ↗
2025-Q3—$35M$409M+ $60M short-term inv.$45M-$71M operating cash flowreport ↗
2025-Q2——$0.7M—-$0.3M operating cash flowreport ↗
2025-Q1—$21M$1.0M$0.5M-$0.7M operating cash flowreport ↗
2024-Q4—$20M$1.7M+ $125M short-term inv.$20M-$0.1M operating cash flowreport ↗
2024-Q3—$18M$1.8M—-<$0.1M operating cash flowreport ↗
2024-Q2——$1.8M—-<$0.1M operating cash flowreport ↗
2024-Q1——$1.8M—-$0.6M operating cash flowreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$121M$374M+ $52M short-term inv.$34M-$114M operating cash flowreport ↗

BBOT did not disclose revenue for 2025. R&D expenses were $121.2M, up 65.8% YoY from $73.11M, and the company reported a full-year net loss of $134.04M. Cash and equivalents were $373.82M as of December 31, 2025, while cash, cash equivalents, and marketable securities totaled $425.5M.

Management expects the cash runway to fund operations into 2028. Clinically, BBOT reported preliminary data across its three RAS-pathway programs: BBO-8520 showed a 65% objective response rate in KRAS G12C NSCLC with a potentially differentiated liver toxicity profile, BBO-11818 produced the first publicly disclosed confirmed panKRAS monotherapy partial response in pancreatic ductal adenocarcinoma, and BBO-10203 showed no hyperglycemia with full target engagement. Updated clinical readouts for all three programs are expected in the second half of 2026, with internal combination studies anticipated to open later in 2026. The company also completed its de-SPAC business combination with Helix Acquisition Corp. II and began trading as BBOT on Nasdaq in August 2025.

View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$73M$1.7M+ $125M short-term inv.—-$0.8M operating cash flowreport ↗
2023-FY——$0.3M<$0.1Mreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($185). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Cobo Marc · Principal Accounting OfficerOpen-market sale78$2.37$185Form 4
2026-10-21Cobo Marc · Principal Accounting OfficerTax withholding203$2.68$544Form 4
2026-10-01Ben Yong · Chief Med & Dev OfficerTax withholding1,047$3.94$4KForm 4
2026-10-01Beltran Pedro · director, President and CEOTax withholding1,047$3.94$4KForm 4
2026-10-01Elmelech Idan · COO & Principal Financial OfcrTax withholding343$3.94$1KForm 4
2026-10-01Cobo Marc · Principal Accounting OfficerTax withholding126$3.94$496Form 4
2026-09-10Cobo Marc · Principal Accounting OfficerAward / grant9,038——Form 4
2026-09-10Cobo Marc · Principal Accounting OfficerTax withholding203$5.52$1KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 66 reporting institutions held 57.5M shares ($510.0M, 71.6% of shares outstanding).

#InstitutionSharesValue
1Cormorant Asset Management, LP17,878,594$160.0M
2DEERFIELD MANAGEMENT COMPANY, L.P.4,885,446$43.7M
3Omega Fund Management, LLC3,289,661$29.4M
4EcoR1 Capital, LLC2,823,126$25.3M
5Alphabet Inc.2,823,126$25.3M
6WELLINGTON MANAGEMENT GROUP LLP2,818,348$25.2M
7ENAVATE SCIENCES GP, LLC2,626,946$23.5M
8CITADEL ADVISORS LLC2,528,762$22.6M
9NOVO HOLDINGS A/S2,185,923$19.6M
10BlackRock, Inc.2,088,297$18.7M
11Laurion Capital Management LP1,922,656$17.2M
12ARMISTICE CAPITAL, LLC1,328,000$11.9M
13Aisling Capital Management LP1,018,018$9.1M
14Paradigm Biocapital Advisors LP868,213$7.8M
15Octagon Capital Advisors LP719,000$6.4M